CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
INO-1001drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00271765
NCT00271765Phase 2Completed

A Phase II Randomized, Placebo-Controlled, Single-Blind, Multi-Center Dose-Escalation Study to Evaluate Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of a Single Intravenous Administration of INO-1001 in Subjects With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Inotek Pharmaceuticals Corporation·interventional·Posted Jan 4, 2006·Updated Nov 29, 2006

In Brief

A Phase 2 clinical trial evaluating INO-1001 for Acute Myocardial Infarction. Completed, across 16 sites in 2 countries.

Detailed Summary

The primary purpose of this study is to assess the safety of INO-1001 in subjects who have experienced a heart attack and are to be treated with coronary angioplasty.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesIsrael, United States
Collaborators--

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 4, 2006
Enrollment StartJan 1, 2004
Study CompletionJun 1, 2006
TodayJul 2, 2026
Posted 20.5 years ago

Interventions

INO-1001drug